IL-17 induces expression of vascular cell adhesion molecule through signalling pathway of NF-κB, but not Akt1 and TAK1 in vascular smooth muscle cells

Scandinavian Journal of Immunology

Volumn 77, Issue 4, 2013, Pages 230-237

  Zhang, H ^a,b   Chen, J ^c   Liu, X ^c   Awar, L ^a   Mcmickle, A ^a   Bai, F ^b   Nagarajan, S ^d,e   Yu, S ^a  

^a ARKANSAS STATE UNIVERSITY   (United States)

^b DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^c UNIVERSITY OF MISSOURI   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-17; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 3; TRANSCRIPTION FACTOR RELA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84875580486     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12030     Document Type: Article

References (42)

1. Hemdan NY, Birkenmeier G, Wichmann G et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun Rev 2010;9:785-92.
2. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010;10:479-89.
3. Iwakura Y, Ishigame H, SAijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011;34:149-58.
4. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 + T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-41.
5. Lee YK, Turner H, Maynard CL et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009;30:92-107.
6. McGeachy MJ, Bak-Jensen KS, Chen Y et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007;8:1390-7.
7. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs Th-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8:967-74.
8. Chen Z, Laurence A, Kanno M et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 2006;103:8137-42.
9. Wei LA, Laurence A, Elias KM, O'Shea JJ. IL-21 is produced by Th17 cells and drives IL-17 production in a ATAt3-dependent manner. J Biol Chem 2007;282:34605-10.
10. Mathur AN, Chang HC, Zisoulis DG et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol 2007;178:4901-7.
11. Ivanov II, McKenzie BS, Zhou L et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17 + T helper cells. Cell 2006;126:1121-33.
12. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-51.
13. Roussel L, Houle F, Chan C et al. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 2010;184:4531-7.
14. Taleb S, Romain M, Ramkhelawon B et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009;206:2067-207.
15. Eid RE, Rao DA, Zhou J et al. Interleukin-17 and interferon-γ are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009;119:1424-32.
16. Cheng X, Yu X, Ding YJ et al. The Th17/Treg functional imbalance in patients with acute coronary syndrome. Clin Immunol 2008;127:89-97.
17. Chen S, Shimada K, Zhang W, Huang G, Crother TR, Arditi M. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumonide infection-accelerated atherosclerosis in mice. J Immunol 2010;185:5619-27.
18. Gao Q, Jiang Y, Ma T et al. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol 2010;185:5820-7.
19. Cybulsky MI, Iiyama K, Li H et al. A major role for VCAM-1, but, not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107:1255-62.
20. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008;28:812-9.
21. Awane M, Andres PG, Li DJ, Reinecker HC. NF-κB-inducing kinase is a common mediator of IL-17-, TNF-α-, and IL-1β-induced chemokine promoter activation in intestinal epithelial cells. J Immunol 1999;162:5337-44.
22. Liu XM, Peyton KJ, Ensenat D et al. Nitric oxide stimulates heme oxygenase-1 gene transcription via the Nrf2/ARE complex to promote vascular smooth muscle cell survival. Cardiovasc Res 2007;175:381-9.
23. Lee H, Hermann A, Deng J et al. Persistently activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell 2009;15:283-93.
24. Yu S, Fang Y, Sharp GC, Braley-Mullen H. Transgenic expression of TGF-beta on thyrocytes inhibits development of spontaneous autoimmune thyroiditis and increases regulatory T cells in thyroids of NOD.H-2 h4 mice. J Immunol 2010;184:5352-9.
25. Iademarco MF, McQuillan JJ, Rosen GD, Dean DC. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). J Biol Chem 1992;267:16323-9.
26. Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T. Functional analysis of human vascular cell adhesion molecule 1 promoter. J Exp Med 1992;176:1583-93.
27. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell 2008;132:344-62.
28. Gaffen SL. Structure and signaling in the IL-17 receptor family. Nat Rev Immunol 2009;9:556-67.
29. Huang F, Kao CY, Wachi S, Thai P, Ryu J, Wu R. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J Immunol 2007;179: 6504-13.
30. He JQ, Saha SK, Kang JR, Zamegar B, Cheng G. Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway. J Biol Chem 2007;282:3688-94.
31. Lamothe B, Besse A, Campos AD, Webster WK, Wu H, Darnay BG. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem 2007;282:4102-12.
32. Schwandner R, Yamaguchi K, Cao H. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med 2000;191:1233-9.
33. Zhu S, Pan W, Shi P et al. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression interleukin 17 receptor signaling. J Exp Med 2010;207:2647-62.
34. Zepp J, Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol 2011;32:232-9.
35. Patel DN, King CA, Bailey SR et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta. J Biol Chem 2007;282:27229-38.
36. Erbel C, Chen L, Bea F et al. Inhibition of IL-17A attenuates atherosclerosis lesion development in ApoE-deficient mice. J Immunol 2009;183:8167-75.
37. Schnyder B, Schnyder-Candrian S, Pansky A et al. IL-17 reduces TNF-induced rantes and VCAM-1 expression. Cytokine 2005;31:191-202.
38. Kim KW, Cho ML, Park MK et al. Increased interleukin-17 production via phosphoinositide 3-kinase/Akt and nuclear factor kappa B-dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther 2005;7:R139-48.
39. Courties G, Seiffart V, Presumey J et al. In vivo RNAi-mediated silencing of TAK1 decreases inflammatory TH1 and Th17 cells through targeting of myeloid cells. Blood 2010;116:3505-16.
40. Alagbala AA, Wang Q, Cui J et al. TAK1 negatively regulates NF-κB and p38 MAP kinase activation in Gr-1(+) CD11b(+) neutrophils. Immunity 2012;36:43-54.
41. Sato S, Sanjo H, Takeda K, et al. Essential function for the kinase TAK1 in innate and adaptive immune response. Nat Immunol 2005;6:1087-95.
42. Cheng G, Wei L, Xiurong W et al. IL-17 stimulates migration of carotid artery vascular smooth muscle cells in an MMP-9 dependent manner via p38 MAPK and ERK1/2-dependent NF-kappa B and AP-1 activation. Cell Mol Neurobiol 2009;29:1161-8.